The Australian Ovarian Cancer market size stood at around USD 52.19 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Ovarian cancer is a type of cancer that mainly occurs in the reproductive part of the women i.e., the ovary. This condition is characterized by abnormal growth of cells in the ovaries, which has the potential to destroy other body parts such as abdomen layers, the lining of the bowel and bladder, lymph nodes, and the liver. Inflating, pelvic ache, abdominal puffiness, and loss of appetite are some of the major symptoms of ovary cancer. The risk of ovarian cancer is higher among women who have ovulated more over their lifetime, which can also include females who have begun ovulating at a very young age.
The rising prevalence of Ovarian cancer, greater use of combination therapies for the treatment of ovarian cancer, and increasing population of aged women are key market drivers which act as a fuelling agent for market growth.
The combination used most often is carboplatin (or cisplatin) and a taxane, such as paclitaxel (Taxol), given IV (into a vein) for 6 cycles. The targeted drug bevacizumab (Avastin) might be given along with chemo as well.
In the year ending 30 June 2019, the number of people aged 85 years and over increased by 12,600 people (2.5%) to reach 515,700. There were more females (317,600) than males (198,100) in this age group.
Ovarian cancer was the 10th most diagnosed cancer among females in Australia in 2015. In 2020, it is estimated that it will remain the 10th most diagnosed cancer among females. In 2015, there were 1,365 new cases of ovarian cancer diagnosed in Australia. In 2020, it is estimated that 1,532 new cases of ovarian cancer will be diagnosed in Australia.
In 2016, there were 938 deaths from ovarian cancer in Australia. In 2020, it is estimated that there will be 1,068 deaths.
In 2011–2015, females diagnosed with ovarian cancer had a 46% chance of surviving for five years compared to their counterparts in the general Australian population.
At the end of 2014, there were 1,120 females living who had been diagnosed with ovarian cancer that year, 4,147 females living who had been diagnosed with ovarian cancer in the previous 5 years.